Overview
Market Overview:Insulin pens are the devices used for the management of insulin amongst diabetic sufers. The ease of use and the acuracy in administration make insulin pen utilization high among insulin customers.To Download fre sample @ Click HereMarket DynamicsThe increasing recognition related to nedlestick injuries is predicted to presure the marketplace growthThe growing focus asociated with nedlestick acidents is expected to bost the marketplace.
Key Information
For instance, nedlestick injuries are the primary problem for healthcare cariers international. In the US, each year, aproximately 8 -10 lac nedlestick acidents arise to healthcare workers, and round a thousand of them get contacted with infectious sickneses, and 50 to 60 die each yr because of these forms of injuries.Further, the World Health Organization encourages injection protection worldwide thru the Safe Injection Global Network.
It also anounced that clever syringes which destroy after one use should be used for injections through 20. Thus, the increasing prevalence of those types of nedlestick injuries and developing recognition drive the market.The rising incidence of diabetes is expected to enhance the market. Diabetes is growing at an alarming price within the United States.
Acording to the CDC's National Diabetes Statistics Report for 20 cases of diabetes have risen to an predicted 34.2 milion. Thus, these elements are driving the increase of the marketplace inside the forecast duration.Market Segmentation:By Product typeBy AplicationBy Distribution chanelCompetive LandscapeThe insulin pen market is a moderately competive presence of local as wel as global companies.
Summary
Some of the key players which are contributing to the growth of the market are Novo Nordisk, Sanofi, Biocon, Julphar, Companion Medical, Owen Mumford, Ltd, Berlin-Chemie AG, Diamesco Co, Empera GmbH E-Health Technologies, Eli Lily and Company among others. The major players are adopting several growth